Canadian Cancer Trials Group

This study tests two drugs, sunitinib and temsirolimus, in 137 people with rare advanced cancers that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants must have one of several rare tumor types, such as certain sarcomas or thyroi…

This study compares two types of brachytherapy (radiation placed directly into the prostate) for men with localized prostate cancer. One uses high-dose radiation given in two sessions, the other uses low-dose radiation from permanent seeds. The goal is to see which better control…

This study tests new combinations of drugs for people with aggressive B-cell lymphoma that has returned or not responded to standard treatment. The goal is to see if these combinations can shrink or eliminate tumors better than current options. About 129 participants will receive…

This study is for people with advanced solid tumors that cannot be cured. It tests two immunotherapy drugs, durvalumab and tremelimumab, given alone or with standard chemotherapy. The main goal is to find safe doses and see how well the drugs shrink or control the cancer.

This study tests whether adding the drug durvalumab to standard treatment (surgery, chemotherapy, and radiation) helps prevent bladder cancer from coming back. About 82 adults with muscle-invasive bladder cancer that hasn't spread will take part. The goal is to see if the combina…

This phase 3 trial tests whether adding the experimental drug ipatasertib to standard hormone therapy (fulvestrant) can slow the growth of advanced ER-positive, HER2-negative breast cancer. The study enrolls 250 people whose cancer worsened after initial treatment with a CDK 4/6 …

This study tests two immunotherapy drugs, durvalumab and tremelimumab, with or without chemotherapy, in 301 people with stage IV non-small cell lung cancer. The goal is to see if these drugs help the immune system fight cancer and improve overall survival. Participants must have …

This study tests a new treatment called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells, against standard chemotherapy (docetaxel) in 200 men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to se…

This study tests whether adding targeted radiation or surgery to all visible cancer spots (up to 5) improves outcomes for men with prostate cancer that has spread to a few places. About 400 men with hormone-sensitive prostate cancer are randomly assigned to get either standard ho…

This study tests whether taking aspirin (a common anti-inflammatory drug) can reduce the risk of ovarian cancer in women with BRCA1 or BRCA2 gene mutations, who are at high risk. About 117 women will take either aspirin or a placebo daily for up to 2 years before their scheduled …

This study is for people with a low-risk type of throat cancer linked to HPV. It tests whether doctors can safely skip radiation to some lymph node areas to reduce side effects, without increasing the chance of the cancer coming back. About 103 participants will receive this adju…